Abstract
The use of B-cell targeted therapies for the treatment of systemic lupus erythematosus (SLE) has generated great interest owing to the multiple pathogenic roles carried out by B cells in this disease. Strong support for targeting B cells is provided by genetic, immunological and clinical observations that place these cells at the center of SLE pathogenesis, as initiating, amplifying and effector cells. Interest in targeting B cells has also been fostered by the successful use of similar interventions to treat other autoimmune diseases such as rheumatoid arthritis, and by the initial promise shown by B-cell depletion to treat SLE in early studies. Although the initial high enthusiasm has been tempered by negative results from phase III trials of the B-cell-depleting agent rituximab in SLE, renewed vigor should be instilled in the field by the convergence of the latest results using agents that inhibit B-cell-activating factor (BAFF, also known as BLyS and tumor necrosis factor ligand superfamily, member 13b), further analysis of data from trials using rituximab and greatly improved understanding of B-cell biology. Combined, the available information identifies several new avenues for the therapeutic targeting of B cells in SLE.
Key Points
-
B cells have antibody-dependent and antibody-independent functions that can either promote or inhibit autoimmunity
-
B-cell-targeted therapies would ideally eliminate pathogenic B cells or promote the expansion and function of protective B cells, or both
-
Despite clinical observations of benefit and results from early trials, two large phase III, randomized placebo-controlled trials of rituximab have failed to meet their primary or secondary clinical endpoints
-
More-selective B-cell depletion achieved by blocking B-cell-activating factor (using belimumab) has demonstrated considerable clinical benefit
-
Improved knowledge of the biology of B cells and plasma cells opens the door to several additional strategies for the therapeutic targeting of B cells
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Manjarrez-Orduno, N., Quach, T. D. & Sanz, I. B cells and immunological tolerance. J. Invest. Dermatol. 129, 278–288 (2009).
Yanaba, K. et al. B-lymphocyte contributions to human autoimmune disease. Immunol. Rev. 223, 284–299 (2008).
Lund, F. E. Cytokine-producing B lymphocytes—key regulators of immunity. Curr. Opin. Immunol. 20, 332–338 (2008).
Lu, T. et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 61, 482–487 (2009).
Leandro, M. J. & de la Torre, I. Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases; lessons from B cell-depletion therapy. Clin. Exp. Immunol. 157, 191–197 (2009).
Navarra, S. et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. Presented at the American College of Rheumatology 2009 Annual Scientific Meeting (2009).
Lovgren, T. et al. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum. 54, 1917–1927 (2006).
Sanz, I. The conundrum of B cell depletion in SLE. Nat. Rev. Rheumatol. 5, 304–305 (2009).
Anolik, J. H. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50, 3580–3590 (2004).
Radbruch, A. et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6, 741–750 (2006).
Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67, 1011–1016 (2008).
Matsushita, T., Yanaba, K., Bouaziz, J. D., Fujimoto, M. & Tedder, T. F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118, 3420–3430 (2008).
Blair, P. A. et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J. Immunol. 182, 3492–3502 (2009).
Rafei, M. et al. A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat. Med. 15, 1038–1045 (2009).
Fillatreau, S., Gray, D. & Anderton, S. M. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat. Rev. Immunol. 8, 391–397 (2008).
Blair, P. A. et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32, 129–140 (2010).
Barcellos, L. F. et al. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet. 5, e1000696 (2009).
Clark, E. A. & Ledbetter, J. A. How does B cell depletion therapy work, and how can it be improved? Ann. Rheum. Dis. 64 (Suppl.), iv77–iv80 (2005).
Merrill, J. T. et al. Efficacy and safety of rituximabin moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222–233 (2010).
Wallace, D. New therapies in systemic lupus erythematosus—trials, troubles and tribulations—working towards a solution: part 2—the politically incorrect version. Lupus 18, 101–103 (2009).
Anolik, J. et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 56, 3044–3056 (2007).
Duddy, M. et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178, 6092–6099 (2007).
Looney, R. J. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580–2589 (2004).
Albert, D. et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann. Rheum. Dis. 67, 1724–1731 (2008).
Dass, S. et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 58, 2993–2999 (2008).
Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67, 1011–1016 (2008).
Cancro, M. P. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann. Rheum. Dis. 65 (Suppl. 3), 34–36 (2006).
Sanz, I., Wei, C., Lee, F. E.-H. & Anolik, J. Phenotypic and functional heterogeneity of human memory B cells. Semin. Immunol. 20, 67–82 (2008).
Yazawa, N., Hamaguchi, Y., Poe, J. C. & Tedder, T. F. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl Acad. Sci. USA 102, 15178–15183 (2005).
Jacobi, A. M. et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann. Rheum. Dis. 67, 450–457 (2008).
Petri, M. et al. Clinically meaningful improvements with epratuzumab (anti-CD22 mAb targeting B-cells) in patients with moderate/severe systemic lupus erythematosus (SLE) flares: results from 2 randomized controlled trials [abstract 1087]. Arthritis Rheum. 58 (Suppl.), S571 (2008).
Tarasenko, T., Dean, J. A. & Bolland, S. FcγRIIB as a modulator of autoimmune disease susceptibility. Autoimmunity 40, 409–417 (2007).
Xiang, Z. et al. FcγRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 8, 419–429 (2007).
Moser, K. L., Kelly, J. A., Lessard, C. J. & Harley, J. B. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun. 10, 373–379 (2009).
Mackay, M. et al. Selective dysregulation of the FcγIIB receptor on memory B cells in SLE. J. Exp. Med. 203, 2157–2164 (2006).
Dhodapkar, K. M. et al. Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J. Exp. Med. 204, 1359–1369 (2007).
Moisini, I. & Davidson, A. BAFF: a local and systemic target in autoimmune diseases. Clin. Exp. Immunol. 158, 155–163 (2009).
Moir, S. et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J. Exp. Med. 200, 587–600 (2004).
Avery, D. T. et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. 112, 286–297 (2003).
Jacobi, A. M. et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 62, 201–210 (2010).
Lesley, R. et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20, 441–453 (2004).
Liu, W. et al. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum. 50, 1884–1896 (2004).
Kalled, S. L. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin. Immunol. 18, 290–296 (2006).
Petri, M. et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 58, 2453–2459 (2008).
Wallace, D. J. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168–1178 (2009).
GlaxoSmithKline. GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus [online], (2009).
Anolik, J. H. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50, 3580–3590 (2004).
Wei, C. et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J. Immunol. 178, 6624–6633 (2007).
Jacobi, A. M. et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95. Arthritis Rheum. 58, 1762–1773 (2008).
Odendahl, M. et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165, 5970–5979 (2000).
Dall'Era, M. et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 56, 4142–4150 (2007).
Dall'Era, M. & Wofsy, D. Systemic lupus erythematosus clinical trials—an interim analysis. Nat. Rev. Rheumatol. 5, 348–351 (2009).
Ghosh, D. & Tsokos, G. C. Spleen tyrosine kinase: An Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases. Autoimmunity 43, 48–55 (2010).
Bahjat, F. R. et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 58, 1433–1444 (2008).
Xie, C. et al. PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr. Int. Immunol. 19, 509–522 (2007).
Barber, D. F. et al. PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11, 933–935 (2005).
Rommel, C., Camps, M. & Ji, H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 7, 191–201 (2007).
Li, Y. et al. B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J. Immunol. 181, 2961–2972 (2008).
Christensen, S. R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417–428 (2006).
Braun, D., Caramalho, I. & Demengeot, J. IFN-α/β enhances BCR-dependent B cell responses. Int. Immunol. 14, 411–419 (2002).
Bekeredjian-Ding, I. B. et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174, 4043–4050 (2005).
Giordani, L. et al. IFN-α amplifies human naive B cell TLR-9-mediated activation and Ig production. J. Leukoc. Biol. 86, 261–271 (2009).
Thibault, D. et al. Type I IFN receptor controls B cell expression of nucleic acid sensing toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Res. Ther. 11, R112 (2009).
Barrat, F. J. & Coffman, R. L. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev. 223, 271–283 (2008).
Barrat, F. J., Meeker, T., Chan, J. H., Guiducci, C. & Coffman, R. L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37, 3582–3586 (2007).
Yao, Y. et al. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60, 1785–1796 (2009).
Lenert, P., Brummel, R., Field, E. H. & Ashman, R. F. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J. Clin. Immunol. 25, 29–40 (2005).
Lampropoulou, V. et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol. 180, 4763–4773 (2008).
Hron, J. D. & Peng, S. L. Type I IFN protects against murine lupus. J. Immunol. 173, 2134–2142 (2004).
Li, J. et al. Deficiency of type I interferon contributes to SLE2-associated component lupus phenotypes. Arthritis Rheum. 52, 3063–3072 (2005).
Obeng, E. A. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907–4916 (2006).
Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14, 748–755 (2008).
van der Heijden, J. W. et al. The proteasome inhibitor bortezomib inhibits the release of NFκB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin. Exp. Rheumatol. 27, 92–98 (2009).
San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906–917 (2008).
Tian, J. et al. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol. 167, 1081–1089 (2001).
Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D. & Anderton, S. M. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3, 944–950 (2002).
Wei, B. et al. Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc. Natl Acad. Sci. USA 102, 2010–2015 (2005).
Zhong, X. et al. Reciprocal generation of Th1/Th17 and Treg by B1 and B2 B cells. Eur. J. Immunol. 37, 2400–2404 (2007).
Hu, C.-Y. et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117, 3857–3867 (2007).
Chen, X. & Jensen, P. E. Cutting Edge: primary B lymphocytes preferentially expand allogeneic FoxP3+ CD4 T cells. J. Immunol. 179, 2046–2050 (2007).
Evans, J. G. et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J. Immunol. 178, 7868–7878 (2007).
Yanaba, K. et al. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28, 639–650 (2008).
Matsushita, T., Yanaba, K., Bouaziz, J.-D., Fujimoto, M. & Tedder, T. F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118, 3420–3430 (2008).
Clatworthy, M. R. et al. B-cell-depleting induction therapy and acute cellular rejection. N. Engl. J. Med. 360, 2683–2685 (2009).
Dass, S., Vital, E. M. & Emery, P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 56, 2715–2718 (2007).
Yazawa, N., Hamaguchi, Y., Poe, J. C. & Tedder, T. F. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl Acad. Sci. USA 102, 15178–15183 (2005).
Sawalha, A. H. et al. Genetic association of IL-21 polymorphisms with systemic lupus erythematosus. Ann. Rheum. Dis. 67, 458–461 (2008).
Ettinger, R. et al. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J. Immunol. 178, 2872–2882 (2007).
Avery, D. T. et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med. 207, 155–171 (2010).
Illei, G. G. et al. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 62, 542–552 (2010).
Anolik, J. H. et al. Cutting Edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J. Immunol. 180, 688–692 (2008).
Hsu, H.-C. et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat. Immunol. 9, 166–175 (2008).
Doreau, A. et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol. 10, 778–785 (2009).
Grammer, A. C. & Lipsky, P. E. CD154–CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum. 46, 1417–1429 (2002).
Huang, W. et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 46, 1554–1562 (2002).
Vinuesa, C. G., Sanz, I. & Cook, M. C. Dysregulation of germinal centres in autoimmune disease. Nat. Rev. Immunol. 9, 845–857 (2009).
Gaspal, F. M. C. et al. Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory. J. Immunol. 174, 3891–3896 (2005).
Murdoch, C. CXCR4: chemokine receptor extraordinaire. Immunol. Rev. 177, 175–184 (2000).
Nanki, T. et al. Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. Arthritis Res. Ther. 11, R149 (2009).
Linterman, M. A. et al. Follicular helper T cells are required for systemic autoimmunity. J. Exp. Med. 206, 561–576 (2009).
Zheng, B. et al. CXCL13 neutralization reduces the severity of collagen-induced arthritis. Arthritis Rheum. 52, 620–626 (2005).
Yellin, M. et al. A phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) [abstract 414]. Arthritis Rheum. 60 (Suppl.), S153 (2009).
Genovese, M. C. et al. Efficacy and safety of baminercept in the treatment of rheumatoid arthritis (RA)—results of the phase 2B study in the TNF-IR population [abstract 417]. Arthritis Rheum. 60 (Suppl.), S154 (2009).
Palanichamy, A. et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J. Immunol. 182, 5982–5993 (2009).
Ngo, V. N. et al. Lymphotoxin α/β and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J. Exp. Med. 189, 403–412 (1999).
Allen, C. D. C., Okada, T. & Cyster, J. G. Germinal-center organization and cellular dynamics. Immunity 27, 190–202 (2007).
Acknowledgements
Supported in part by NIH grants U19 AI56390 (Rochester Autoimmunity Center of Excellence) and R01 AI049660 to I. Sanz, and K23 AI67501 to F. E.-H. Lee.
Désirée Lie, Univesity of California, Orange, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr. Sanz has served as a paid consultant for Genentech (attendance of a B-cell summit meeting) and GlaxoSmithKline and has received research support from Biogen; research support from GlaxoSmithKline is pending. Dr. Lee declares no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Sanz, I., Lee, FH. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 6, 326–337 (2010). https://doi.org/10.1038/nrrheum.2010.68
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.68
This article is cited by
-
MAIT cells and their implication in human oral diseases
Inflammation Research (2022)
-
Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis
BMC Rheumatology (2021)
-
CP-25 alleviates antigen-induced experimental Sjögren's syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration
Laboratory Investigation (2021)
-
Generation and characterization of CD19-iCre mice as a tool for efficient and specific conditional gene targeting in B cells
Scientific Reports (2021)
-
Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus
Clinical Pharmacokinetics (2020)